Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Teriparatide is the recombinant N-terminal fragment 1-34 of human parathyroid hormone (PTH). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis. Unlike antiresorptive agents, studies attribute to it an effect that stimulates new bone formation.
Researched for
Postmenopausal osteoporosisOsteoporosis in menGlucocorticoid-induced osteoporosisReduction of fracture risk
Official status
US: Prescription
In the United States, teriparatide (brand name Forteo) has been FDA-approved as a prescription medicine for the treatment of osteoporosis in individuals at high fracture risk since 2002.
Teriparatide corresponds to the biologically active first 34 amino acids of human parathyroid hormone and binds the PTH-1 receptor on bone and kidney cells. The literature describes that intermittent receptor activation preferentially stimulates the activity of bone-forming osteoblasts, whereas continuously elevated PTH exposure (as in hyperparathyroidism) tends to favor bone resorption. This time-dependent difference is regarded as the mechanistic basis for the bone-anabolic effect observed in studies.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
3 observations · single evidence tier
Human RCT
3
03
What the studies show
Human RCT
Mensch
Neer RM et al. 2001
Reduction in the incidence of new vertebral fractures in postmenopausal women with osteoporosis compared with placebo.
What does NOT follow: Observed in a randomized, placebo-controlled registration trial in a defined population of postmenopausal women with pre-existing vertebral fractures; not generalizable to other populations or routes of administration.
Human RCT
Mensch
Neer RM et al. 2001
Increase in lumbar spine bone mineral density relative to baseline in clinical trials.
What does NOT follow: Bone mineral density is a surrogate marker; changes do not necessarily equate to clinical benefit in every individual and were measured under trial conditions.
Human RCT
Mensch
Kendler DL et al. 2018
Lower incidence of new vertebral fractures in a head-to-head comparison with an antiresorptive agent in women with severe osteoporosis.
What does NOT follow: Active-controlled comparison in a high-risk population; results reflect the relative difference between two drug classes and are context-dependent.
04
Where studies disagree
Open question
Does teriparatide raise the risk of osteosarcoma in humans?
POSITION A
In rat studies, osteosarcoma occurred in a dose- and duration-dependent manner — leading to a boxed warning and a time limit on therapy.
POSITION B
Long-term human post-marketing surveillance found no correspondingly raised osteosarcoma signal at the expected magnitude.
CURRENT STATE · The rat warning led to a treatment-duration limit; human data are reassuring, but caution remains for at-risk groups.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 1 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
In approved use and in clinical trials, teriparatide is administered subcutaneously. This statement describes the documented trial and approval context and does not constitute a usage instruction.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Adverse events reported in clinical trials include, among others, nausea, limb pain, headache, and dizziness.
Frequency and severity are derived from controlled trial populations and cannot be directly extrapolated to individuals.
Animal model
In preclinical studies in rats, an increased occurrence of osteosarcoma was observed under high, long-duration exposure, which historically led to a regulatory boxed warning; this was later removed by the FDA after evaluation of human data.
Finding from an animal model with high exposure; human relevance was not confirmed in long-term observation, which is why the warning was removed by regulators.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
The daily injection and the time limit on therapy are frequently discussed; a common worry concerns the osteosarcoma warning derived from animal studies.
recurring in osteoporosis communities
Not supported by studies: The osteosarcoma warning derives from rat studies; later human post-marketing surveillance did not confirm a correspondingly raised risk at the expected magnitude. Treatment duration is limited by regulators.
10b
What online communities discuss
Recurring themes from Reddit, Quora and patient forums — synthetically summarised, sources linked. Not scientific evidence, but a signal of what users report. Deliberately separated from the study base.
Non-scientific sources. What users report in forums — synthetically summarised, paraphrased, with link to source. Not validated by studies.
Sorted by discussion frequency · 1 Thema
Discussion frequency: ~176 aggregated reviews
On drugs.com, teriparatide (Forteo) holds an average user rating of 5.4 out of 10 across roughly 176 reviews — 38% positive, 38% negative. Commonly named are back/joint pain, leg cramps, nausea, dizziness and flu-like symptoms; positive reports highlight gains in bone density.
What this does NOT mean:Review platforms are self-selected, unblinded and not representative; the figures are a snapshot (as of June 2026) and change continuously. They do not replace controlled data — see the studies section. The exactly split rating reflects highly variable tolerability.
In the United States, teriparatide (brand name Forteo) has been FDA-approved as a prescription medicine for the treatment of osteoporosis in individuals at high fracture risk since 2002.
2026-06-07
Germany
Prescription
In Germany, teriparatide (brand name Forsteo) is available as a prescription medicine for the treatment of osteoporosis via the centralized EMA authorization; biosimilars are additionally approved.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial